TOM DAVIS, VIRGINIA, CHAIRMAN

DAN BURTON, INDIANA
CHRISTOPHER SHAYS, CONNECTICUT
ILEANA ROS-LEHTINEN, FLORIDA
JOHN M. MCHUGH, NEW YORK
JOHN L. MICA, FLORIDA
MARK E. SOUDER, INDIANA
STEVEN C. LATOURETTE, OHIO
DOUG OSE, CALIFORNIA
RON LEWIS, KENTUCKY
JO ANN DAVIS, VIRGINIA
TODD RUSSELL PLATTS, PENNSYLVANIA
CHRIS CANNON, UTAH
ADAM H. PUTNAM, FLORIDA
EDWARD L. SCHROCK, VIRGINIA
JOHN J. DUNCAN, JR., TENNESSEE
NATHAN DEAL, GEORGIA
CANDICE MILLER, MICHIGAN
TIM MURPHY, PENNSYLVANIA
MICHAEL R. TURNER, OHIO
JOHN R. CARTER, TEXAS
MARSHA BLACKBURN, TENNESSEE
PATRICK J. TIBERI, OHIO

ONE HUNDRED EIGHTH CONGRESS

## Congress of the United States

## House of Representatives

COMMITTEE ON GOVERNMENT REFORM 2157 RAYBURN HOUSE OFFICE BUILDING WASHINGTON, DC 20515-6143

> MAJORITY (202) 225–5074 FACSIMILE (202) 225–3974 MINORITY (202) 225–5051 TTY (202) 225–6852

www.house.gov/reform

HENRY A. WAXMAN, CALIFORNIA, RANKING MINORITY MEMBER

TOM LANTOS, CALIFORNIA
MAJOR R. OWENS, NEW YORK
EDOLPHUS TOWNS, NEW YORK
PAUL E. KANJORSKI, PENNSYLVANIA
CAROLYNB, MALONEY, NEW YORK
ELJAH E. CUMMINGS, MARYLAND
DENNIS J. KUCINICH, OHIO
DANNY K. DAVIS, ILLINOIS
JOHN F. TIERNEY, MASSACHUSETTS
WM. LACY CLAY, MISSOURI
DIANE E. WATSON, CALIFORNIA
STEPHEN F. LYNCH, MASSACHUSETTS
CHIS VAN HOLLEN, MARYLAND
LINDA T. SANCHEZ, CALIFORNIA
C.A. DUTCH RUPPERSBERGER,
MARYLAND
LEANOR HOLMES NORTON,
DISTRICT OF COLUMBIA
JIM COOPER, TENNESSEE
BETTY MCCOLLUM, MINNESOTA

BERNARD SANDERS, VERMONT,

October 15, 2004

The Honorable Deborah Platt Majoras Chairman Federal Trade Commission 600 Pennsylvania Avenue, N.W. Washington, D.C. 20580

Dear Chairman Majoras:

As you aware, on October 5, 2004, the British government's Medicines and Healthcare Products Regulatory Agency suspended the Chiron Corporation's influenza vaccine manufacturing license effective immediately for three months because of manufacturing problems. As a result, the U.S. will not receive the 46-48 million flu shots Chiron planned to provide this season. This number accounts for nearly half of the nation's supply.

On Friday, October 8, 2004 the Committee held a hearing to examine the contributing factors that led to the influenza vaccine shortage, the public health implications of the vaccine shortage, and the U.S. government and vaccine manufacturers' plans to address this problem. As a result of information provided during the hearing and recent news articles regarding Chiron's suspension, the Committee is investigating the circumstances surrounding the flu vaccine shortage.

The shortage in flu vaccine has caused widespread concern among the public. The Centers for Disease Control and Prevention (CDC) has tried to address these concerns by working diligently to educate the public as to how to respond to the flu vaccine shortage and how to identify those people who classify as priority recipients of the vaccine.

It has been brought to our attention, however, that despite the CDC's efforts, certain wholesalers and distributors are taking advantage of public fears by price gouging the flu vaccine. An October 13, 2004 *New York Times* article entitled, "U.S. Begins Investigation of Vaccine Supplier," reported the Kansas Office of the Attorney General filed a lawsuit against drug distributor, Meds-Stat, citing the distributor for price gouging

Chairman Deborah Platt Majoras October 15, 2004 Page 2

in an attempt to sell the vaccine for over 10 times the actual cost. According to an October 14, 2004 *South Florida Sun-Sentinel* article, entitled "State sues Fort Lauderdale Wholesaler for Gouging Price of Flu Vaccine," Florida's Office of Attorney General also filed suit against Meds-Stat for selling five vials of flu vaccine at more than \$900 each. Today's *Washington Post* article, entitled "Some Supplies Jack up Flu Vaccine Price," stated that reports of flu vaccine price gouging have occurred all over the country, including California and West Virginia.

Yesterday, the Department of Health and Human Services Secretary Tommy G. Thompson, sent a letter to the Attorney General of each state urging them to fully investigate reports of price gouging of the flu vaccine and prosecute those engaged in the activity "to the full extent of the law." Secretary Thompson announced the CDC would be sharing its reports of price gouging with the states.

It is not unlikely that these unconscionable price increases will occur in other states. In light of the press accounts reporting such incidents, we ask that you immediately begin an inquiry to determine: (a) the pervasiveness of the flu vaccine price gouging; (b) whether there is <u>any</u> justification for such increase in prices; and (c) what enforcement actions the FTC has already taken or plans to take. Please provide the Committee with a briefing on your findings and any recommendations or suggestions you believe should be taken to prevent such activities from occurring during a future vaccine shortage.

Thank you for your timely attention to this matter. If you have any questions about this request, please contact Anne Marie Turner, Majority Counsel, at (202) 225-5074, or Sarah Despres, Minority Professional Staff, at (202) 225-5420.

Sincerely,

Tom Davis

Chairman

Ranking Minority Member